Hellenic Society Of Hematology — Sponsor Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

2 Recruiting

7 Completed trials

1 Countries active

12 Unique IMPs

100% Results reported

Phase II

Phase I/II

Phase II: 7 Phase I/II: 2

100%

7 of 7 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Acute myeloid leukaemia 1 FLT3 gene mutation 1

Top IMPs

BELANTAMAB MAFODOTIN 5 DARATUMUMAB 2 BORTEZOMIB 1 GILTERITINIB 1 ISATUXIMAB 1

All trials

9 total

Administration of Gilteritinib to eliminate MRD in patients with AML and FLT3-ITD mutation. Pending

2025-521875-30-00 Phase II 1 country GILTERITINIB
A trial aiming to investigate the safety and efficacy of a new drug in patients with primary immune thrombocytopenia previously treated with… Recruiting

2023-509131-12-01 Phase II 1 country BELANTAMAB MAFODOTIN
An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of … Recruiting

2024-518263-35-00 Phase II 1 country BORTEZOMIB; DARATUMUMAB
A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in comb… Ended

2024-517723-39-00 Phase II 1 country BELANTAMAB MAFODOTIN
A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMB… Ended

2024-516147-32-00 Phase I/II 1 country BELANTAMAB MAFODOTIN; DARATUMUMAB
A Phase 2 Study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM Patients who received one prior line of therapy conta… Ended

2024-516060-28-00 Phase II 1 country ISATUXIMAB
Belantamab Mafodotin in combination with Daratumumab, Lenalidomide and Dexamethasone for the treatment of patients with newly diagnosed mul… Ended

2024-515634-32-00 Phase I/II 1 country BELANTAMAB MAFODOTIN
A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of Belantamab Mafodotin administered in comb… Ended

2024-515988-55-00 Phase II 1 country BELANTAMAB MAFODOTIN
A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide mai… Ended

2024-516061-36-00 Phase II 1 country

Showing 1–9 of 9 trials

← All sponsors A–Z